Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $17.25.

ENTA has been the topic of a number of recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Robert W. Baird dropped their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Finally, HC Wainwright reduced their target price on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, December 24th.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 13.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its holdings in Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock worth $958,000 after acquiring an additional 8,645 shares in the last quarter. Rhumbline Advisers grew its position in shares of Enanta Pharmaceuticals by 4.7% in the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 1,548 shares during the period. American Century Companies Inc. increased its stake in shares of Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 7,287 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after purchasing an additional 18,003 shares during the last quarter. Finally, US Bancorp DE lifted its stake in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Trading Down 0.2 %

NASDAQ ENTA opened at $5.53 on Monday. Enanta Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $17.80. The company has a fifty day simple moving average of $6.73 and a two-hundred day simple moving average of $10.46. The stock has a market cap of $117.20 million, a P/E ratio of -1.01 and a beta of 0.56.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s revenue was down 22.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.33) EPS. As a group, sell-side analysts forecast that Enanta Pharmaceuticals will post -4.93 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.